Latest Ivantis Financing Increases Series B to $71 Million

Represented Ivantis, developer of the novel Hydrus Microstent device designed to lower eye pressure for glaucoma patients, in securing an additional $25 million in its Series B financing. This additional $25 million takes the total Series B to $71 million, making it one of the largest medical device financings of the past year. The latest close in the Series B includes new investor Foresite Capital, plus returning investors New Enterprise Associates (NEA), Delphi Ventures, Ascension Ventures, Vertex Ventures, GBS Ventures, EDBI, and MemorialCare Innovation Fund. The funds will support the Company’s multiple ongoing clinical trials, including the US pivotal trial, and is expected to take the Company through U.S. approval.